Holen Sie sich die Stockscreener-App
2.05
5.53%
-0.12
Schlusskurs vom Vortag:
$2.17
Offen:
$2.21
24-Stunden-Volumen:
440.44K
Relative Volume:
1.02
Marktkapitalisierung:
$56.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.94M
KGV:
-0.5339
EPS:
-3.84
Netto-Cashflow:
$-22.97M
1W Leistung:
-21.15%
1M Leistung:
+0.49%
6M Leistung:
-61.10%
1J Leistung:
-65.83%
1-Tages-Spanne:
$2.05
$2.21
1-Wochen-Bereich:
$2.05
$3.18
52-Wochen-Spanne:
$1.11
$17.88
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.05 | 56.12M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Annovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC Wainwright - Defense World
Annovis Bio (ANVS) Price Target Cut by 60% by HC Wainwright | AN - GuruFocus
Annovis Bio stock price target cut to $12 at H.C. Wainwright By Investing.com - Investing.com South Africa
Annovis Bio stock price target cut to $12 at H.C. Wainwright - Investing.com Nigeria
Annovis Bio (ANVS) Price Target Slashed by H.C. Wainwright | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates - citybuzz -
Annovis to Host Webinar and Live Q&A on June 24, 2025 - GlobeNewswire
Annovis Bio, Inc. to Host Live Webcast on Neurodegenerative Disease Developments and Phase 3 Trial Updates - Nasdaq
Annovis CEO Reveals Latest Alzheimer's Phase 3 Data and FDA Feedback on Parkinson's Program - Stock Titan
Annovis Bio (ANVS) Stock Surges Over 28% | ANVS Stock News - GuruFocus
Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Jane Street Group LLC - Defense World
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail
Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus
Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus
Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Manila Times
Annovis Bio Appoints New Principal Financial Officer - TipRanks
Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com
Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq
Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -
Annovis Bio hires new director of biostatistics amid AD trial - Investing.com
Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com
Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan
LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):